Endpoints News’ Post

Every so often, (and hopefully more often) the Endpoints News Health Tech crew goes deep on a topic we're fascinated by. In today's newsletter, Shelby Livingston and Ngai Yeung got inside the changing world of medical scribes, once a booming, human-run operation that's now grappling with an AI future and venture-backed startups to compete with. AI documentation startups have been on my radar if not only for the hundreds of millions they've raised, but also because it feels like one of the clearest cut places where AI is entering hospitals. What happens here could have implications on future uses: (Bonus: Please enjoy the rare newsletter emoji care of Drew Armstrong !!) https://lnkd.in/gQU8yZxd

NEW: Terray Therapeutics becomes the latest AI-focused biotech startup to raise a megaround, just closing a $120 million Series B round. Founding CEO Jacob Berlin, PhD told me his Los Angeles-area biotech aims to enter the clinic in 2026 with its first drug candidate. In the meantime, they will keep scaling a massive dataset of protein-ligand binding interactions. Today that data is 50x larger than what's publicly available, he said, and he believes this is the "key dataset missing for AI-driven drug discovery." “Every single molecule we bring forward has a scaffold that has been de novo discovered and optimized at Terray from the ground up,” Berlin told me. “That’s totally different than what you see across the ecosystem, where AI models have to stay close to historical sets of data because they don’t have our hardware innovation.” My latest exclusive for Endpoints News, including some details on how they developed a partial latent diffusion model to generate new small molecules:

What happens when a public company gets an activist investor? Reporter Max Bayer talked to people who have gone toe-to-toe with Starboard Value to preview the fight with Pfizer for Endpoints News. Spoiler: It's gonna get personal. https://lnkd.in/eBVKZZRk